The high-resolution crystal structure of human LCAT
- J Lipid Res. 2015 Sep;56(9):1711-9. doi: 10.1194/jlr.M059873.
- 1. Therapeutic Discovery Amgen Inc., South San Francisco, CA 94080.
- 2. Therapeutic Discovery, Amgen Inc., Seattle, WA 98119.
- 3. Metabolic Disorders, Amgen Inc., South San Francisco, CA 94080.
- 4. Therapeutic Discovery, Amgen Inc., Burnaby, BC V5A1V7, Canada.
LCAT is intimately involved in HDL maturation and is a key component of the reverse Cholesterol transport (RCT) pathway which removes excess Cholesterol molecules from the peripheral tissues to the liver for excretion. Patients with loss-of-function LCAT mutations exhibit low levels of HDL Cholesterol and corneal opacity. Here we report the 2.65 Å crystal structure of the human LCAT protein. Crystallization required enzymatic removal of N-linked glycans and complex formation with a Fab fragment from a tool antibody. The crystal structure reveals that LCAT has an α/β hydrolase core with two additional subdomains that play important roles in LCAT function. Subdomain 1 contains the region of LCAT shown to be required for interfacial activation, while subdomain 2 contains the lid and Amino acids that shape the substrate binding pocket. Mapping the naturally occurring mutations onto the structure provides insight into how they may affect LCAT enzymatic activity.